請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56895
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉宏輝(Horng-Huei Liou) | |
dc.contributor.author | Li Lin | en |
dc.contributor.author | 林立 | zh_TW |
dc.date.accessioned | 2021-06-16T06:30:53Z | - |
dc.date.available | 2020-08-27 | |
dc.date.copyright | 2020-08-27 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-27 | |
dc.identifier.citation | 1. Dravet, C., et al., Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol, 2005. 95: p. 71-102. 2. Wu, Y.W., et al., Incidence of Dravet Syndrome in a US Population. Pediatrics, 2015. 136(5): p. e1310-5. 3. Chipaux, M., et al., Unusual consequences of status epilepticus in Dravet syndrome. Seizure, 2010. 19(3): p. 190-4. 4. Dravet, C., The core Dravet syndrome phenotype. Epilepsia, 2011. 52(s2): p. 3-9. 5. Dravet, C. and H. Oguni, Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol, 2013. 111: p. 627-33. 6. Aras, L.M., J. Isla, and A. Mingorance-Le Meur, The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav, 2015. 44: p. 104-9. 7. Battaglia, D., et al., Cognitive decline in Dravet syndrome: is there a cerebellar role? Epilepsy Res, 2013. 106(1-2): p. 211-21. 8. Li, B.M., et al., Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav, 2011. 21(3): p. 291-5. 9. Griffin, A., et al., Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening. Front Pharmacol, 2018. 9: p. 573. 10. Marini, C., et al., The genetics of Dravet syndrome. Epilepsia, 2011. 52 Suppl 2: p. 24-9. 11. Ogiwara, I., et al., Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci, 2007. 27(22): p. 5903-14. 12. Bender, A.C., et al., SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome. Epilepsy Behav, 2012. 23(3): p. 177-86. 13. Escayg, A. and A.L. Goldin, Sodium channel SCN1A and epilepsy: mutations and mechanisms. Epilepsia, 2010. 51(9): p. 1650-8. 14. Jiang, X., M. Lachance, and E. Rossignol, Involvement of cortical fast-spiking parvalbumin-positive basket cells in epilepsy. Prog Brain Res, 2016. 226: p. 81-126. 15. Quadrato, G., M.Y. Elnaggar, and S. Di Giovanni, Adult neurogenesis in brain repair: cellular plasticity vs. cellular replacement. Front Neurosci, 2014. 8: p. 17. 16. Götz, M., M. Nakafuku, and D. Petrik, Neurogenesis in the Developing and Adult Brain-Similarities and Key Differences. Cold Spring Harb Perspect Biol, 2016. 8(7). 17. Urbán, N. and F. Guillemot, Neurogenesis in the embryonic and adult brain: same regulators, different roles. Front Cell Neurosci, 2014. 8(396). 18. Cha, B.H., et al., Spontaneous recurrent seizure following status epilepticus enhances dentate gyrus neurogenesis. Brain Dev, 2004. 26(6): p. 394-7. 19. Parent, J.M., et al., Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J Neurosci, 1997. 17(10): p. 3727-38. 20. Parent, J.M., The role of seizure-induced neurogenesis in epileptogenesis and brain repair. Epilepsy Res, 2002. 50(1-2): p. 179-89. 21. Neuberger, E.J., et al., Enhanced Dentate Neurogenesis after Brain Injury Undermines Long-Term Neurogenic Potential and Promotes Seizure Susceptibility. Stem Cell Reports, 2017. 9(3): p. 972-984. 22. Frampton, J.E., Stiripentol: A Review in Dravet Syndrome. Drugs, 2019. 79(16): p. 1785-1796. 23. Wirrell, E.C. and R. Nabbout, Recent Advances in the Drug Treatment of Dravet Syndrome. CNS Drugs, 2019. 33(9): p. 867-881. 24. Guerrini, R., et al., Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia, 1998. 39(5): p. 508-12. 25. Mantegazza, M., et al., Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol, 2010. 9(4): p. 413-24. 26. Fisher, J.L., The effects of stiripentol on GABA(A) receptors. Epilepsia, 2011. 52 Suppl 2(0 2): p. 76-8. 27. Whitlow, R.D., et al., The anticonvulsant valproate increases the turnover rate of gamma-aminobutyric acid transporters. J Biol Chem, 2003. 278(20): p. 17716-26. 28. Wirrell, E.C., Treatment of Dravet Syndrome. Can J Neurol Sci, 2016. 43 Suppl 3: p. S13-8. 29. Steinhäuser, C. and V. Gallo, News on glutamate receptors in glial cells. Trends Neurosci, 1996. 19(8): p. 339-345. 30. Niswender, C.M. and P.J. Conn, Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol, 2010. 50: p. 295-322. 31. Traynelis, S.F., et al., Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev, 2010. 62(3): p. 405-96. 32. Lahti, A.C., et al., Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology, 2001. 25(4): p. 455-67. 33. Rung, J.P., et al., (+)-MK-801 induced social withdrawal in rats; a model for negative symptoms of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(5): p. 827-32. 34. Rogawski, M.A., Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr, 2011. 11(2): p. 56-63. 35. Steeds, H., R.L. Carhart-Harris, and J.M. Stone, Drug models of schizophrenia. Ther Adv Psychopharmacol, 2015. 5(1): p. 43-58. 36. Chater, T.E. and Y. Goda, The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity. Front Cell Neurosci, 2014. 8(401). 37. Greger, I.H., J.F. Watson, and S.G. Cull-Candy, Structural and Functional Architecture of AMPA-Type Glutamate Receptors and Their Auxiliary Proteins. Neuron, 2017. 94(4): p. 713-730. 38. Amakhin, D.V., et al., Seizure-Induced Potentiation of AMPA Receptor-Mediated Synaptic Transmission in the Entorhinal Cortex. Front Cell Neurosci, 2018. 12(486). 39. Man, H.Y., GluA2-lacking, calcium-permeable AMPA receptors--inducers of plasticity? Curr Opin Neurobiol, 2011. 21(2): p. 291-8. 40. Diering, G.H. and R.L. Huganir, The AMPA Receptor Code of Synaptic Plasticity. Neuron, 2018. 100(2): p. 314-329. 41. Ho, M.T., et al., Developmental expression of Ca2+-permeable AMPA receptors underlies depolarization-induced long-term depression at mossy fiber CA3 pyramid synapses. J Neurosci, 2007. 27(43): p. 11651-62. 42. Lee, H.K., Ca-permeable AMPA receptors in homeostatic synaptic plasticity. Front Mol Neurosci, 2012. 5: p. 17. 43. Rajasekaran, K., M. Todorovic, and J. Kapur, Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol, 2012. 72(1): p. 91-102. 44. Rakhade, S.N. and F.E. Jensen, Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol, 2009. 5(7): p. 380-91. 45. Twomey, E.C., et al., Mechanisms of Channel Block in Calcium-Permeable AMPA Receptors. Neuron, 2018. 99(5): p. 956-968.e4. 46. Frey, N., et al., The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs. Epilepsia, 2017. 58(12): p. 2178-2185. 47. Greenwood, J. and J. Valdes, Perampanel (Fycompa): A Review of Clinical Efficacy and Safety in Epilepsy. P t, 2016. 41(11): p. 683-698. 48. Rosenfeld, W., et al., Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol, 2015. 19(4): p. 435-45. 49. Rogawski, M.A. and T. Hanada, Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl, 2013(197): p. 19-24. 50. Hanada, T., The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov, 2014. 9(4): p. 449-58. 51. Lattanzi, S. and P. Striano, The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery. Expert Opin Drug Discov, 2019. 14(3): p. 195-197. 52. Mohammad, H., et al., Perampanel but Not Amantadine Prevents Behavioral Alterations and Epileptogenesis in Pilocarpine Rat Model of Status Epilepticus. Mol Neurobiol, 2019. 56(4): p. 2508-2523. 53. Wu, T., et al., The neuroprotective effect of perampanel in lithium-pilocarpine rat seizure model. Epilepsy Res, 2017. 137: p. 152-158. 54. Rugg-Gunn, F., Adverse effects and safety profile of perampanel: A review of pooled data. Epilepsia, 2014. 55(s1): p. 13-15. 55. Mazzocchetti, P., et al., Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. Neurobiol Dis, 2020. 140: p. 104848. 56. Luttjohann, A., P.F. Fabene, and G. van Luijtelaar, A revised Racine's scale for PTZ-induced seizures in rats. Physiol Behav, 2009. 98(5): p. 579-86. 57. Greenfield, L.J., Jr., Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure, 2013. 22(8): p. 589-600. 58. Lado, F.A. and S.L. Moshé, How do seizures stop? Epilepsia, 2008. 49(10): p. 1651-64. 59. Dong Xue, Z.-G.H., Kimberley Barnes, Howard J. Lesiuk, Karen E. Smith, and Alastair M. Buchan, Delayed Treatment with AMPA, but Not NMDA, Antagonists Reduces Neocortical Infarction. J Cereb Blood Flow Metab, 1994. 60. Kim, J.E., et al., Perampanel Affects Up-Stream Regulatory Signaling Pathways of GluA1 Phosphorylation in Normal and Epileptic Rats. Front Cell Neurosci, 2019. 13: p. 80. 61. Gulati, P., et al., Amino Acids Activate mTOR Complex 1 via Ca2+/CaM Signaling to hVps34. Cell Metabolism, 2008. 7(5): p. 456-465. 62. Li, R.J., et al., Regulation of mTORC1 by lysosomal calcium and calmodulin. Elife, 2016. 5. 63. Slipczuk, L., et al., BDNF activates mTOR to regulate GluR1 expression required for memory formation. PLoS One, 2009. 4(6): p. e6007. 64. Fortin, D.A., et al., Brain-Derived Neurotrophic Factor Activation of CaM-Kinase Kinase via Transient Receptor Potential Canonical Channels Induces the Translation and Synaptic Incorporation of GluA1-Containing Calcium-Permeable AMPA Receptors. The Journal of Neuroscience, 2012. 32(24): p. 8127-8137. 65. 徐瑞鴻, Scn1a基因突變調控神經幹細胞之增生與分化. 國立台灣大學碩士論文, 2015. 66. 許筠, 細胞週期在SCN1A突變中對於神經幹細胞發育之調控角色研究. 國立台灣大學碩士論文, 2016. 67. Goldberg, E.M. and D.A. Coulter, Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction. Nat Rev Neurosci, 2013. 14(5): p. 337-49. 68. Cho, K.O., et al., Aberrant hippocampal neurogenesis contributes to epilepsy and associated cognitive decline. Nat Commun, 2015. 6: p. 6606. 69. Jessberger, S. and J.M. Parent, Epilepsy and Adult Neurogenesis. Cold Spring Harb Perspect Biol, 2015. 7(12). 70. Garza-Lombó, C. and M.E. Gonsebatt, Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function. Frontiers in Cellular Neuroscience, 2016. 10(157). 71. Ryskalin, L., et al., mTOR-Dependent Cell Proliferation in the Brain. BioMed research international, 2017. 2017: p. 7082696-7082696. 72. LiCausi, F. and N.W. Hartman, Role of mTOR Complexes in Neurogenesis. International journal of molecular sciences, 2018. 19(5): p. 1544. 73. 蔡哲文, Dravet症候群小鼠之癲癇易感性及癲癇行程之研究. 國立台灣大學碩士論文, 2019. 74. Wirrell, E.C., et al., Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. Pediatr Neurol, 2017. 68: p. 18-34.e3. 75. Cuartero, M.I., et al., Abolition of aberrant neurogenesis ameliorates cognitive impairment after stroke in mice. J Clin Invest, 2019. 129(4): p. 1536-1550. 76. Kaushik, G. and K.S. Zarbalis, Prenatal Neurogenesis in Autism Spectrum Disorders. Front Chem, 2016. 4: p. 12. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56895 | - |
dc.description.abstract | Dravet症候群,又稱為嬰兒期嚴重肌陣攣性癲癇(SMEI),是一種罕見且具耐藥性的癲癇性腦部病變。Dravet症候群患者除了會表現出自發性反復癲癇發作外,也容易在高溫下被誘導出癲癇發作症狀。大約90%的Dravet症候群患者與電壓敏感型鈉離子通道(voltage-gate sodium channel)Nav1.1亞型之SCN1A基因的功能喪失突變相關,進而導致PV+ GABAergic中樞神經元功能失調和GABA的釋放不足,造成整體腦神經迴路的過度興奮。此外,我們先前的研究發現Scn1aE1099X/+小鼠具有異常過度神經新生的情形,這可能在epileptogenesis當中扮演了關鍵性的角色。由於臨床上valproic acid、clobazam和stiripentol等藥物藉由促進GABA神經傳遞所達到的治療效果相當有限,因此我們換個角度思考抑制glutamate的神經傳遞是否能更有效地控制患者的病情。AMPA受體為一glutamate受體,在中樞神經系統中負責快速的突觸訊號傳遞,而perampanel為目前臨床上唯一被使用的AMPA受體拮抗劑。在這篇研究當中,我們使用Scn1aE1099X/+小鼠來探索perampanel的治療效果和當中可能涉及的抗癲癇機制。首先,我們評估了Perampanel對Dravet症候群小鼠自發性反覆癲癇發作的影響。結果表示,perampanel不僅可以預防自發性複發性癲癇發作的發生,而且可以減少EEG紀錄當中interictal spikes的次數。在高溫誘導癲癇發作的實驗中,我們發現1 mg / kg和2 mg / kg的perampanel無論在敏感性和嚴重性上均對高溫誘導癲癇發作均具有顯著的改善效果。在高溫誘導癲癇發作的實驗中,我們進一步測試了其他抗癲癇藥(如stiripentol,valproic acid和phenytoin)的治療效果。在這些藥物中,只有valproic acid可以降低高溫誘導癲癇發作的敏感性,但是皆無法改善高溫誘導癲癇發作的嚴重程度。為了評估perampanel除了單純抑制AMPA受體所介導的電流外是否還有其他抗癲癇作用,我們進行了連續七天給予Perampanel的實驗。在給予perampanel一星期後,我們注意到perampanel具有降低Dravet症候群小鼠海馬迴中AMPA受體次單元GluA1的蛋白質表達的能力。此外,perampanel還可以改善Dravet症候群小鼠異常過度神經新生的活性。這些發現提供了證據,說明perampanel是個相當具有潛力的Dravet症候群治療藥物。 | zh_TW |
dc.description.abstract | Dravet syndrome (DS), also known as Severe Myoclonic Epilepsy in Infancy (SMEI), is a catastrophic and drug-resistant epileptic encephalopathy. Patients with Dravet syndrome exhibit spontaneous recurrent seizures and are prone to induce seizure symptoms under high temperatures. About 90% of patients with Dravet syndrome are associated with loss-of-function mutations in the sodium voltage-gated channel alpha subunit 1 (SCN1A) gene, which in turn leads to the dysfunction of PV+ GABAergic interneurons and insufficient GABA release, causing excessive excitation of the overall brain neural circuit. Our previous study discovered that Scn1aE1099X/+ mice had aberrant excessive neurogenesis, which may play a key role in epileptogenesis. Since the therapeutic effects of promoting GABA neurotransmission by valproic acid, clobazam and stiripentol are quite limited clinically, we considered whether inhibiting glutamate neurotransmission can control the patient's condition more effectively. AMPA receptor is one of the glutamate receptors that mediates fast synaptic transmission in the central nervous system, and perampanel is the first and only clinically used AMPA receptor antagonist. In this study, we used Scn1aE1099X/+ mice to explore the therapeutic effects and possible antiepileptic mechanisms of perampanel. First, we evaluated the effect of perampanel on spontaneous recurrent seizure in Dravet syndrome mice. Results showed that perampanel can not only prevent the occurrence of spontaneous recurrent seizures, but also decrease the number of interictal spikes in EEG recording. In the hyperthermia-induced seizure experiment, we found that both 1 mg/kg and 2 mg/kg of perampanel have significant therapeutic effects on hyperthermia-induced seizures in both susceptibility and severity. We further tested the therapeutic effect of other anti-epileptic drugs such as stiripentol, valproic acid and phenytoin in the hyperthermia-induced seizure experiment. Among these drugs, only valproic acid had the ability to decrease hyperthermia-induced seizure susceptibility, but none of the drugs affected hyperthermia-induced seizure severity. To evaluate whether perampanel has other antiepileptic effects apart from only inhibiting the AMPA receptor-mediated currents, we conducted an experiment in which perampanel was administered for seven consecutive days. After one week of perampanel administration, we noticed that it has the ability to decrease the protein level of AMPA receptor subunits GluA1 in hippocampus in Dravet syndrome mice. In addition, perampanel can also decrease the aberrant neurogenesis activity in Dravet syndrome mice. These findings provide evidence that perampanel is a promising drug for Dravet syndrome therapy. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:30:53Z (GMT). No. of bitstreams: 1 U0001-2307202014352700.pdf: 8518548 bytes, checksum: 6aefc8fca58531f88e4edd4056934e2a (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | 誌謝 I 中文摘要 II ABSTRACT IV CONTENTS VI LIST OF FIGURES IX CHAPTER 1 INTRODUCTION 1 1.1 Characteristics of Dravet Syndrome 1 1.2 Causes of Dravet Syndrome 1 1.3 Neurogenesis in Epilepsy 2 1.4 Treatments for Dravet Syndrome 2 1.5 Possible New Therapeutic Targets for Dravet Syndrome 3 1.6 The Characteristics of AMPA Receptors and Their Role in Epilepsy 4 1.7 The Characteristics and Application of Perampanel 5 1.8 Aim of Study 6 CHAPTER 2 MATERIALS AND METHODS 7 2.1 Animals 7 2.2 Electroencephalography Electrode Implantation 7 2.3 The Procedure of Hyperthermia-Induced Seizure 8 2.4 Drug Administration 8 2.5 Western Blot 9 2.6 Neural Stem Cell Culture 9 2.7 Perfusion and Cryosection 10 2.8 Immunofluorescence 11 2.9 Data Analysis 11 2.10 Statistical Analysis 12 2.11 Antibodies 13 CHAPTER 3 RESULTS 14 3.1 Effect of Perampanel on SRS Events in Dravet Syndrome Mice 14 3.2 Effect of Perampanel on Hyperthermia-Induced Seizure 15 3.3 Effect of Other Antiepileptic Treatments on Hyperthermia-Induced Seizure 17 3.4 Effect of Combination Therapy on Hyperthermia-Induced Seizure 18 3.5 Effect of Perampanel on AMPA Receptor Subunits Expression 18 3.6 Effect of Perampanel on Neurogenesis in Dravet Syndrome Mice 19 CHAPTER 4 DISCUSSION 21 4.1 Overview 21 4.2 Perampanel Compared to Other Treatments 22 4.3 NBQX may Cause Nephrotoxicity 23 4.4 Oral Perampanel has Great Bioavailability 23 4.5 Perampanel Decrease GluA1 expression in Dravet Syndrome Mice 24 4.6 Perampanel Decrease Aberrant Neurogenesis of Dravet Syndrome Mice 24 4.7 Intracellular Calcium Concentration of Neural Stem Cells 25 4.8 Conclusion 26 CHAPTER 5 FIGURES 27 REFERENCE 62 | |
dc.language.iso | zh-TW | |
dc.title | AMPA受體拮抗劑Perampanel對於Dravet症候群動物模式之治療效果及抗癲癇機轉 | zh_TW |
dc.title | The Therapeutic Effect and Antiepileptic Mechanism of AMPA Receptor Antagonist Perampanel in a Mouse Model of Dravet Syndrome | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.advisor-orcid | 劉宏輝(0000-0001-6537-5346) | |
dc.contributor.oralexamcommittee | 林琬琬(Wan-Wan Lin),符文美(Wen-Mei Fu),張芳嘉(Fang-Chia Chang) | |
dc.contributor.oralexamcommittee-orcid | 林琬琬(0000-0002-3207-734X),符文美(0000-0003-4157-8987),張芳嘉(0000-0003-0271-5416) | |
dc.subject.keyword | Perampanel,Dravet症候群,癲癇,SCN1A,AMPA受體,神經新生, | zh_TW |
dc.subject.keyword | Perampanel,Dravet syndrome,epilepsy,SCN1A,AMPA receptor,neurogenesis, | en |
dc.relation.page | 69 | |
dc.identifier.doi | 10.6342/NTU202001781 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-07-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-2307202014352700.pdf 目前未授權公開取用 | 8.32 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。